InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066  Version 2 .0: 10 JUL 2017  
 
Confidential  Page 1 of 46  CLINICAL INVESTIGATION PLAN  
Study Title:  An In Vivo Recovery and Survival Study of Platelets Collected on 
the Trima Accel System and Stored in InterSol Solution  
Study Number:  CTS-5066 
Study  Device:  Trima AccelÂ® Apheresis system  and InterSol Solution  
Manufacturer:  Terumo  BCT, Inc. 
10811 West Collins Avenue 
Lakewood, CO 80214 USA  
Phone: (303) 231-4832 
Sponsor:  Terumo  BCT, Inc. 
10811 West Collins Avenue Lakewood, CO 80214 USA  
Phone: (303) 231-4832 
Contact: Heather Pidcoke, MD,  PhD  
Phone: (303) 231-4832 
Email: Heather.Pidcoke@terumobct.com  
This study will be  conducted according to this Clinical Investigation Plan , Good Clinical Practice 
as described in the International Conference of Harmonisation Guidance for Industry E6, and as 
applicable, U nited S tates Food and Drug Administration 21 CFR 600-680 and 21 CFR 812, 
International Organization for Standardization  14145:2011(E), and other regulatory requirements 
of the regions where the study is conducted. All essential document s will be archived . 
 
Version/Date:  2.0/10 JUL 2017 
 
Confidentiality Statement 
The information contained in this document, particularly unpublished data, is the property or 
under control of the Sponsor, and is provided to you in confidence as an Investigator, potential 
Investigator, or consultant, for review by you, your staff, and a n applicable Institutional Review 
Board/Ethics Committee. The information is only to be used by you in connection with 
authorized clinical studies of the investigational device described in the Clinical Investigation 
Plan. You will not disclose any of the information to others without written authorization from 
the Sponsor except to the extent necessary to obtain informed consent from those persons who 
may participate in the clinical trial. Please refer to the applicable Master and/or Clinical Trial 
Agreement for complete details regarding applicable confidentiality standards. 
 
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS-5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 3 of 46 AMENDMENT 1 SUMMARY OF CHANGES  
Study Title:  An In Vivo Recovery and Survival Study of Platelets Collected on the Trima 
Accel System and Stored in InterSol  Solution  
CIP #:  CTS-5066  
Amendment Version / Date:  Version 2.0/ 10 JUL 2017  
Replaces CIP Version / Date:  Version 1.0/27 FEB 2017 
Rationale:  This CIP was update d to clarify that participant s are not allowed to take aspirin 
or aspirin containing  medications, non steroidal anti inflammatory drugs 
(NSAIDs ), anti -platelet agents, or other drugs affecting platelet viability  for the 
duration of the study . Because the studyâ€™s primary endpoint s relate to platelet 
survival and recovery, this clarification is necessary to ensure the platelets being 
evaluated are not exposed to drugs affecting their viability throughout the study . 
Additionally, this amendment ensures  participant s are aware that they are not 
permitted  to take these medications , and if they do, they will be discontinued 
from the study. The  inclusion criteria, study procedures, and reason for study 
procedure discontinuation/termination were updated to better clarify this 
requirement . 
 Additionally, this CIP amendment addresses a minor typographical error noted 
by the United States Food and Drug Administration (FDA) in the section of the 
CIP outlining the number of participants . The CIP incorrectly stated â€œan 
approximate 45% screen fail/ early termination rate  which would allow up to  40 
healthy adult participants to be enrolled in this study â€. Applying a 45% screen 
fail/early termination rate would result in total enrollment of 44 subjects. This 
study will only enroll up to 40 healthy adult participants, therefore the 
approximate screen fail/early termination rate was changed from 45% to 40%.  
Administrative changes, typographical error corrections,  abbreviations  and 
minor wording changes for clarity have been made and will not be reflected in 
the table below.  
Section(s)  Used to Read:  Now Reads:  
Synopsis,  Section 10.1 
Number of Participants and Selection, and Section  16.1 
Sample Size  Assuming an approximate 45%  
screen fail/early termination rate, up to 40 healthy adult participants will be enrolled in this study to ensure 24 evaluable data points across 2 investigational sites in the United States.  Assuming an approximate 40% screen 
fail/early termination rate, up to 40 healthy 
adult participants will be enrolled in this study to ensure 24 evaluable data points across 2 investigational sites in the United States.  
Synopsis and Section 10.2 Inclusion Criteria  Has been added  8. Participant s must agree to refrain  
from using aspirin or aspirin containing  
medications, non steroidal anti inflammatory drugs (NSAID s), anti -
platelet agents, or other drugs affecting platelet viability for the duration of the 
study  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS-5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 4 of 46 Table 11 -1 in Section 11 
Study Procedures  Confirm participant is healthy and 
did not take any exclusionary medications on Apheresis Visit and Infusion  Day Confirm participant is healthy  on 
Apheresis Visit and Infusion Day  
Record any medications taken in the  7 
days prior to apheresis procedure and 
through study completion on Apheresis Visit, Infusion Day, and Post-Infusion Days  
Confirm participant  is healthy and  did not 
take any exclusionary medicationb on 
Apheresis Visit, Infusion Day, and Post -
Infusion Days  
Record medications medical 
interventions  to treat any AEs or SAEs  
b Exclusionary medication includes 
aspir in or aspirin containing  
medications, NSAIDs, anti -platelet 
agents , or other drug s affecting platelet 
viability.  
Section 11.2. 1 Prior to 
Apheresis V isit  1.  Confirm participant is healthy 
and did not take any excludable medication if screening visit was prior to apheresis visit  1. Confirm participant is healthy  
2. Record any medications taken in the  7 
days prior to the Apheresis V isit and 
during this visit .  
3. Confirm the participant did not take 
any excludable medication ( see Section 
13) if screening visit was prior to apheresis 
visit 
Secti on 11.2.2 Apheresis 
Procedure; Section 11.4 Infusion Day; Section 11.5.1 
Post Infusion Days 6-12 
(BEST Days 1 -7); 
Section  11.5.2 Post Infusion 
Day 16 Â± 1 day (BEST Day 11 
Â± 1 day)  Record medications or medical interventions to treat AEs or SAEs 
Record medications or  medical 
interventions to treat AEs or SAEs 
Section 11.4 Infusion Day;  
Section 11.5.1 Post Infusion Days 6-12 (BEST Days 1 -7); 
Section 11.5.2 Study Day 16Â±1 da y (BEST Day 11Â±1 
day)  Has been added  2. Record any concomitant medications taken since previous visit and during this visit  
Section 11.5.1 Study  Days 6-
12 (BEST Days 1 -7) and  
Section 11.5.2 Study Day16 Â± 
1 day (BEST Day 11 Â± 1 day)  Has been added  1. Confirm participant did not take any 
exclusionary medication since previous visit 
Section 11.5.1 Study Days 6 -
12 (BEST Days 1 -7) Has been added  2. Record any concomitant medications taken sinc e previous visit and during 
these visits 
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS-5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 5 of 46 Section 11.6 Study Pr ocedure 
Discontinuation/Termination  Has been added  17. Participant took exclusionary 
medication  (see Section 13)  
Section 13 Concomitant Medications  Only medications administered to treat AEs or SAEs will be recorded in the eCRFs.  Participants are prohibited from taking 
aspirin or aspirin containing medications for 7 days prior to the apheresis procedure, and NSAID s, anti -
platelet agents, or other drug s affecting 
platelet viability for 3 days prior to the apheresis procedure.  Once enrolled in the s tudy, participants are prohibited 
from taking these medications throughout their particip ation  in the 
study.   
Concomitant medications taken from the 7 days before the apheresis visit until study exit will be recorded in the eCRFs. 
Medical interventions administered to 
treat AEs or SAEs will be recorded in the 
eCRFs.  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS-5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 6 of 46 SYNOPSIS  
Sponsor:  Terumo BCT, Inc.  
Study Title:  An In Vivo Recovery and Survival Study of Platelets Collected on the Trima Accel 
System and Stored in InterSol Solution  
Study Number:  CTS-5066 
Target Population:  Healthy Adult Volunteer Donors  
Device Description:  The Trima AccelÂ® Automated Blood Collection  system (Trima Accel system) is an 
automated blood component collection system that uses centrifugal force to separate 
donor blood into platelet, plasma, and red blood cell (RBC) components and uses Acid Citrate Dextrose, Formula A (ACD -A) as the anticoagulant. The device is comprised 
of 3 major sub -systems: 1) the Trima machine itself ; 2) sterile, single use disposable 
blood tubing sets ; and 3) embedded software. There are additional optional accessories 
such as plasma bag, platelet bag, seal safe system, and barcode scanner kit.  
Terumo BCTâ€™s Trima Accel system received United States Food and Drug 
Administration (FDA) 510(k) clearance for hyperconcentrated platelet collections on 
17 December  2012 (BK120049).  
Fenwalâ€™s InterSol
Â® was cleared by the FDA on 09 December  2009 (BN080041), as a 
platelet additive solution (PAS) for the replacement of 65% plasma in platelet components for use with Am icusâ„¢ Separator System.  
Intended Use:  The intended use for the Trima Accel system  and PAS (InterSol) combination to be 
evaluated in this investigational s tudy is to use the Trima Accel s ystem to collect 
platelet concentrates from normal healthy donors and  to re-suspend the platelets in 
35% plasma and 65% InterSol for storage and subsequent transfusion into patients requiring blood product support.  
Study Centers Planned:  2 centers in the United States . 
Objective:  The primary objective of this study is to determine the in vivo recovery and survival  of 
radiolabeled platelet s collected on the Trima Accel s ystem , diluted in 65% 
InterSol/35% plasma, and stored for 5 days .  
Efficacy Endpoints : Primary Efficacy Endpoint s: 
The primary endpoint for this study will  be recovery and survival as calculated using 
the COST software.  
1. For recovery: Test â€“ 0.66*Control â‰¥ 0 with a 1 sided 97.5% confidence limit 
2. For survival: Test â€“ 0.58*Control â‰¥ 0 with a 1 sided 97.5% confidence limit 
Safety Endpoint s: Safety will be monitored through the collection of adverse events (AEs), serious  
adverse events (SAEs), and unanticipated adverse device effects (UADEs) from  the 
start of the apheresis procedure venipunc ture until study completion . Products will be 
destroy ed per the siteâ€™s standard operating procedures (SOPs) after all testing has been 
completed.  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS-5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 7 of 46 Inclusion Criteria:  1. Age 18 years or older  
2. Normal health status as per AABB  criteria for healthy donor  
3. Able to commit to the study schedule  
4. Meets the inclusion criteria defined by the Blood Center for apheresis  platelet with 
PAS collection on the Trima Accel system. These criteria are based on FDA 
Regulations and AABB standards. Note: Participants who are deferred from 
volunteer community dona tions because of travel restrictions, piercings, or tattoos 
may participate in the study, as products are not transfused  
5. Participant s of child -bearing potential (either male or female) must agree to use an 
effective method of contraception during the cours e of the study  
6. Female s of childbearing potential must be willing to take a pregnancy test prior to 
infusion of radiolabeled  platelets  
7. Has given written informed consent         
8. Participant must agree to refrain  from using aspirin or aspirin containing  
medic ations, non steroidal anti inflammatory drugs (NSAID s), anti -platelet agents, 
or other drugs affecting platelet viability for the duration of the study  
Exclusion Criteria:  1. Previously received radiation therapy  
2. Has been diagn osed w ith a platelet disorder ( ie, platelet  dysfunction) 
3. Already participated in 4 research studies involving radioisotopes within the contemporaneous calendar -year 
4. Pregnant or nursing females  
5. Participation currently, or within the last 12 months, in another investigational trial 
that would potentially interfere with the analysis of this investigation  
6. History of know n hypersensitivity to indium or chromium  
7. Treatment with aspirin or aspirin containing  medications within 7 days of apheresis  
or treatment with NSAID s, anti -platelet  agents or other drugs affecting platelet 
viability w ithin 3 days of apheresis  (eg, ibuprofen or other NSAIDs)  
Number of Participants   
Planned:  Assuming an approximate 40% screen fail/early termination  rate, up to 40 healthy  
adult participants will be enrolled in this study to ensure 24 evaluable data points  
across  2 investigational sites in the United States.  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS-5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 8 of 46 Study Design:  This is a prospective, open -label, multicenter , controlled study to evaluate in vivo 
recovery and survi val of radiolabeled apheresis platelets collected on the Trima Accel 
system and sto red in 65% InterSol/ 35% plasma for 5 days . 
One ( 1) Test unit will be collected as a hyperconcentrated  platelet product. The Test 
unit will be diluted to a final ratio of 65% InterSol/ 35% plasma . 
After collection, the Test unit will be stored at room temperature with agitation for 
5 days.  
On Day 5, study sites  will follow the â€œPlatelet Radiolabeling  Procedureâ€ published by 
Biomedical Excellence for Safer Transfusion ( BEST ) and their SOPs  for platelet 
radiolabeling, infusion, radioactivity sampling, and recovery and survival calculations . 
Following storage for 5 days, an aliquot of Test platelets will be radiolabeled with 
either 111In or 51Cr. Similarly an aliquot of freshly prepared platelets derived from a 
whole blood  sample  donated on Day 5 (Control) will be tagged with the radiolabel not 
used in the Test platelets. The identity of the label (51Cr or 111In) used for Test and 
Control platelets will be randomized . The labeled aliquots will then be infused 
simultaneously on Day 5  (BEST Day 0)  back to the autologous donor . On Study Day 5 
(BEST Day 0) samples will be drawn at 0 (pre- infusion)  and 2 hours Â± 15 minutes 
post-infusion . Next, 1 sample will be drawn daily (except on weekends) from  Study  
Day 6 thr ough Day 12 (BEST Day  1  Ì¶  7) for a total of 5 samples. To conclude , 1 final 
sample will be drawn on Study Day 15, 16, or 17 (BEST Day 10, 11,  or 12). Recovery 
and survival will be calculated at each site according to the COST software.  
Study Duration:  Study participation will be up to  9 visits.  Screening may be done within 5 days prior to 
the apheresis procedure or combined as 1 visit, which includes screening and the 
apheresis procedure all in 1 day.   
The entire study is anticipated to last approximately 5 months . 
Statistical 
Methodology:  Primary Endpoints:  
The primary endpoint s of this study are to show that recovery and survival of  platelet s 
collected on the Trima Accel system,  diluted in 65% InterSol/35% plasma and stored 
for 5 days meet FDA standards defined by:  
â€¢ For recovery: Test â€“ 0.66*Control â‰¥ 0 with a 1 -sided 97.5% confidence limit 
â€¢ For survival: Test â€“ 0.58*Control â‰¥ 0 with a 1 -sided 97.5% confidence limit 
Recovery (at 24 hours) is expressed as a percentage of the extrapolated platelet count at time 0. Survival is expressed in hours and is approximated using linear regression.  
For each endpoint, paired differences within each participa nt will be used to construct 
the lower limit of a 1-sided 97.5% confidence intervals. If the lower limit is greater 
than 0 for both endpoints, the test product will be declared to meet the FDA  standard.   
 
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS-5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 9 of 46 TABLE OF CONTENTS  
1 INTRODUCTION ......................................................................................................14  
1.1 Background ......................................................................................................14  
2 DEVICE DESCRIPTION .........................................................................................14  
2.1 Trima Accel System Device Description  .........................................................14  
2.2 InterSol Solution  ..............................................................................................16  
3 INTENDED USE STATEMENT .............................................................................17  
4 CLINICAL STUDY EXPERIENCE  ........................................................................17  
5 RATIONALE FOR THE CURRENT STUDY .......................................................18  
6 OBJECTIVE ..............................................................................................................18  
7 EFFICACY ENDPOINTS .........................................................................................18  
7.1 Primary Efficacy Endpoints .............................................................................18  
8 SAFETY ENDPOINTS  .............................................................................................19  
9 INVESTIGATIO NAL PLAN  ...................................................................................19  
9.1 Study Design ....................................................................................................19  
9.2 Study Duration .................................................................................................21  
10 STUDY POPULATION ............................................................................................21  
10.1  Number of Participants and Selection  ..............................................................21  
10.2  Inclusion Criteria  .............................................................................................21  
10.3  Exclusion Criteria  ............................................................................................22  
10.4  Enrollment........................................................................................................22  
11 STUDY PROCEDURES  ...........................................................................................23  
11.1  Screening Visit: Study Days -5 to 0 .................................................................26  
11.2  Apheresis Visit: Study Day 0 ...........................................................................26  
11.2.1  Prior to Apheresis  .............................................................................26  
11.2.2  Apheresis Procedure  .........................................................................26  
11.3  Post Collection Handling: Study Days 0 - 5 ....................................................27  
11.4  Infusion Day: Study Day 5 (BEST Day 0) ......................................................27  
11.5  Post-Infusion Days ...........................................................................................28  
11.5.1  Study Days 6- 12 (BEST Days 1 -7) ...................................................28  
11.5.2  Study Day 16 Â± 1 day (BEST Day 11 Â± 1 day) ................................28  
11.6  Study Procedure Discontinuation/Termination................................................29  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS-5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 10 of 46 11.7  Stopping Rules .................................................................................................30  
12 LABORATORY TESTS  ...........................................................................................30  
12.1  Clinica l Laboratory Tests .................................................................................30  
12.2  Test Product Laboratory Test ...........................................................................30  
12.3  Platelet Radiolabeling Procedures  ...................................................................30  
13 CONCOMITANT MEDICATIONS  ........................................................................30  
14 ADVERSE EVENTS/EFFEC TS ..............................................................................31  
14.1  Anticipated Risks  .............................................................................................31  
14.1.1  Venipuncture Related ........................................................................31  
14.1.2  Apheresis Complications in Healthy Donors ....................................31  
14.1.3  Apheresis Risks with the Trima Accel System  .................................33  
14.1.4  Potential Risks of Infusion of Radiolabeled Platelets .......................33  
14.2  Risk Mitigation  ................................................................................................33  
14.3  Adverse Event Definitions ...............................................................................34  
14.4  Adverse Event Recording ................................................................................34  
14.5  Adverse Event Reporting .................................................................................34  
14.5.1  Severity  .............................................................................................34  
14.5.2  Relationship  ......................................................................................34  
14.6  Adverse Event Follow-up ................................................................................35  
14.7  Serious Adverse Events and Unanticipated Adverse Device Effect ................35  
14.7.1  Definition  ..........................................................................................35  
14.7.2  SAE/UADE Reporting  ......................................................................36  
14.8  Clinical Investigation Plan Deviations  .............................................................37  
14.9  Medical Monitoring  .........................................................................................37  
15 STUDY DEVICE  .......................................................................................................37  
15.1  Device Deficiencies  .........................................................................................37  
15.2  Device Accountability .....................................................................................37  
15.2.1  Receipt of Study Device ...................................................................37  
15.2.2  Storage ..............................................................................................38  
15.2.3  Accountability ...................................................................................38  
16 STATISTICAL PLAN  ...............................................................................................38  
16.1  Sample Size  ......................................................................................................38  
16.2  Outcome Measures ...........................................................................................38  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS-5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 11 of 46 16.2.1  Primary Endpoint ..............................................................................38  
16.2.2  Safety Measures  ................................................................................39  
16.3  Analysis Population .........................................................................................39  
16.4  CIP Analysis Exclusions ..................................................................................39  
17 STUDY MANAGEMENT  .........................................................................................40  
17.1  Investigator Responsibilities  ............................................................................40  
17.1.1  Investigator Agreement  .....................................................................40  
17.1.2  Institutional Review Board  ...............................................................40  
17.1.3  Informed Consent ..............................................................................40  
17.1.4  Study Files and Record Retention .....................................................41  
17.1.5  Regulatory Compliance  ....................................................................41  
17.2  Sponsor Responsibilities ..................................................................................41  
17.2.1  Amendments to the CIP ....................................................................41  
17.2.2  General Responsibilities  ...................................................................41  
17.3  Joint Investigator-Sponsor Responsibilities .....................................................41  
17.3.1  Training  .............................................................................................41  
17.4  Collecting and Recording Data ........................................................................41  
17.4.1  Source Documents ............................................................................42  
17.4.2  Case Report Forms  ............................................................................42  
17.5  CIP Compliance  ...............................................................................................42  
17.6  Termination of the Study .................................................................................42  
17.7  Publication Policy  ............................................................................................42  
18 REFERENCES  ...........................................................................................................44  
 
List of Tables  
Table 11- 1: List of Study Procedures ..................................................................................24  
Table 14- 1: Venipuncture Adverse Event Frequency .........................................................31  
Table 14- 2: Apheresis Adverse Event Frequency  ...............................................................32  
 
List of Figur es 
Figure 2- 1: Components of the Trima Accel System  .........................................................16  
Figure 9- 1: Study Design ....................................................................................................20  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 12 of 46 LIST OF ABBREVIATIONS AND DEFINITION OF TERMS  
111In Indium 111  
51Cr Chromium 51 
ACD -A Anticoagulant Citrate Dextrose, Solution A  
AE Adverse Event  
BEST  Biomedical Excellence for Safer Transfusion  
CBC Complete Blood Count  
CFR Code of Federal Regulations  
CIP Clinical Investigation Plan  
CTA  Clinical Trial Agreement  
CTCAE  Common Terminology Criteria for Adverse Events  
DVT  Deep Vein Thrombosis  
eCRF  Electronic Case Report Form  
EDC Electronic Data Capture  
EDTA  Ethylenediaminetetraacetic A cid 
ESC Extent of Shape Change  
FAS Full Analysis Set  
FDA United States Food and Drug Administration  
GCP  Good Clinical Practice  
HCT  Hematocrit  
HCO3 Bicarbonate  
Hgb Hemoglobin  
HSR  Hypotonic Shock Response  
IC Informed Consent 
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
IRB Institutional Review Board  
ISO International Organization for Standard ization  
IV Intravenous  
LDH Lactate Dehydrogenase  
LOC Loss of Consciousness  
MedDRA  Medical Dictionary For Regulatory Activities  
MOP  
mg Manual of Procedures  
Milligram(s)  
mL Milliliter(s)  
NSAID  Non-steroidal Anti -inflammatory Drugs  
PAS Platelet Additive Solution  
pCO 2 Partial Pressure of Carbon Dioxide  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 13 of 46 PHI Protected Health Information  
pO 2 Partial Pressure of Oxygen  
PVC  Polyvinyl Chloride  
RBC Red Blood Cell  
SAE  Serious Adverse Event  
SD Source Documents  
SOP Standard Operating Procedure  
UADE  Unanticipated Adverse Device Effect  
USID Unique Study Identification  
USP United States Pharmacopeia 
WBC White Blood Cell  
  
  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 14 of 46 1 INTRODUCTION  
1.1 Background 
Platelet transfusions are used extensively for the treatment and prophylaxis of bleeding 
associated with major trauma, surgery , chemotherapy, and in thrombocytopenic individuals (have 
low platelet count) as well as those with  platelet dysfunctions. The p latelets used for platelet 
transfusions are separated from donor blood through either whole blood collections  or advanced 
apheresis techniques. In the United States, the majority of platelets used for transfusion are routinely collected and stored in 100% donor plasma.  
In Europe it is common practice to replace part of the storage plasma with a platelet additive 
solution (PAS). The rationale behind this is that diluting the plasma with PAS may reduce the 
risk of deleterious rea ctions such as allergic reactions because there are fewer  cellular mediators 
present  than found in 100% plasma.
1 Substituting PAS for plasma may have o ther advantages as 
well. Platelet additive solutions have  a more consistent composition than plasma from different 
donors, can be optimized for longer storage, and allow  for a more frugal use of blood 
components since more plasma can then be used for other applications instead of platelet 
storage.2,3 
Platelet additive solutions have been used for over 20 years in Europe. In the United States, the 
first Food and Drug Administration (FDA) approval for the use of PAS was in 2009. This first 
approval was for the use of the InterSol Solution ( a PAS-E) as a replacement of 65% plasma in 
platelet components. A second PAS, IsoplateTM Solution ( a PAS-F), has since been cleared by the 
FDA  (March 5, 2015, BN090067/0). In Europe, platelet additive solutions  and apheresis devices 
are approved separately, but in the United States the use of a PAS is linked to the specific apheresis device used to obtain the platelets. The Isoplate Solution is approved for use with the 
Trima Accel
Â® Automated Blood Collection Sys tem (Trima A ccel system) and the InterSol 
Solution (hereon referred to as InterSol) is approved for use with the AmicusTM Separator System  
(Amicus) . 
Terumo BCT is pursuing FDA clearance for InterSol in combination with the Trima Accel 
system in order to provide blood centers with the option to use InterSol as well as Isoplate Solution when collecting platelets to be stored in a  PAS.  
2 DEVICE DESCRIPTION  
2.1 Trima Accel System Device Description  
The Trima Accel system is an automated blood component collection system that uses 
centrifugal force to separate whole blood into platelet, plasma, and red blood cell (RBC) 
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 15 of 46 components. These blood components are either collected into storage bags, or returned to the 
donor . The Trima Accel system consists of:  
â€¢ The Trima Accel m achine 
â€¢ Embedded software 
â€¢ Disposable tubing s ets 
â€¢ Optional a ccessories, connected to the system which  can include: 
o Accessory storage plasma bag  
o Accessory storage platelet bag  
o Trima Accel seal safe system  
o Trima barcode scanner k it 
The products collected depend on the disposable tubing collection set used, the donor specific parameters (donorâ€™s total blood volume, hematocrit [ HCT ] or hemoglobin [Hgb], and platelet 
count) entered at the time of collection, and the procedure selected. Donor blood type may also be used to limit which blood components are collected.  
The current Trima Accel system equipment is approximately 42 inches tall and 21 inches wide, 
and weighs less th an 200 pounds. The Trima Accel system uses disposable tubing sets with a 
cassette that automatically loads the tubing into the pumps, valves, and sensors. The touch screen 
display is designed to lead the operator through the setup and operating procedures, and provide 
detailed messages to assist in troubleshooting the collection procedures. 
Figure 2-1 identifies the major components of the Trima Accel system . 
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 16 of 46 Figure 2-1: Components of the Trima Accel System  
 a. The IV pole is a metal tube with an arm that 
contains hooks for hanging the product bags. 
The pole is lowered for transport.  
b. The product bags are part of the disposable tubing set. Product bags hold the collected  
RBCs, platelets, and plasma.  
c. The touch- screen display is the screen that is 
used to monitor and control the blood collection procedure. Throughout the procedure, the display guides the operator 
from step to step.  
d. The cassette is part of the disposable tubing set that snaps into place on t he front of the 
system. The cassette guides the flow of 
blood and blood products through the 
system. It also ensures that the tubing is 
positioned so that the pumps, valves, and sensors are loaded automatically.  
e. The 5 pumps are the components that push 
the blood and products through the system.  
f. The filler is designed with a groove in which 
the channel is loaded. The filler comprises 
the top portion of the centrifuge.  
g. The centrifuge is a rotating device that spins 
at up to 3,000 rpm, creating a gravitational force to separate the whole blood into its 
components.  
h. The wheels  can be locked in position to 
stabilize the Trima Accel system during a 
collection procedure or unlocked to easily 
move the Trima Accel system to a new 
location.  
The Trima Accel system was cleared by FDA for the collection of hyperconcentrated platelets 
stored in Isoplate (BK120049) on 17 December 2012 . There will be no modification to the Trima 
Accel device for this study and it will be used as described in the Trima Accel Operatorâ€™s 
Manual.  
The Trima Accel Platelet + Sampler + AutoPAS MultiPlasma, RBC disposable set was cleared 
by the FDA (BK120049) on 17 December 2012. This disposable set will be used for the collection of hyperconcentrated platelets in this study as described in the Trima Accel Operatorâ€™s 
Manual.  
2.2 InterSol Solution  
InterSol, from Fenwalâ„¢, a Fresenius Kabi company, was FDA approved for the storage of 
hyperconcentrated platelets (BN080041) on 09 December 2009. InterSol is an isotonic solution 

InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 17 of 46 designed to replace a proportion of the plasma used in the storage of Amicus derived 
leukoreduced apheresis platelets under standard blood banking conditions. 
The solution contains: sodium acetate as a nutrient, sodium citrate to prevent platelet clumping 
and activation, sodium phosphate for buffering, and sodium chloride for osmolarity. InterSol 
does not have a pharmacological effect in vivo, but rather acts to provide the appropriate environment for platelet storage in lieu of a portion of the plasma normally used. 
InterSol is provided as a 500 mL sterile and non-pyrogenic solution in a non-citrated polyvinyl 
chloride ( PVC ) plastic container with a sterile and non-pyrogenic fluid path. 
Each 100 mL contains 305 mg Dibasic Sodium Phosphate, Anhydrous, United States Pharmacopeia ( USP); 93 mg Monobasic Sodium Phosphate, Monohydrate, USP; 318 mg 
Sodium Citrate, Dihydrate, USP; 442 mg Sodium Acetate, Trihydrate, USP; 452 mg Sodium Chloride, USP; Water for Injection, USP quantity sufficient.
4 
3 INTENDED USE STATEME NT 
The intended use for the Trima Accel system and PAS (InterSol) combination to be evaluated in 
this investigational study is to use the Trima Accel system to collect platelet concentrates from 
normal donors and to re-suspend the platelets in 35% plasma/ 65% InterSol for storage and 
subsequent transfusion into patients requiring blood product support.  
4 CLINICAL STUDY EXPER IENCE  
A randomized, paired, prospective, open-label, multicenter, controlled study was conducted in 
2016 to evaluate the in vitro quality of platelets collected on the Trima Accel system and stored 
for up to 7 days in 65% InterSol/35% plasma (Test) compared to platelets stored in 100% plasma 
(Control). All the Test products had a pH â‰¥ 6.2 after 5 and 7 days of storage and thus met the FDA acceptance criteria for pH.
5,6 
Secondary endpoint analyses of partial pressure of oxygen (pO 2), partial pressure of carbon 
dioxide (pCO 2), bicarbonate (HCO 3-), lactate, glucose, lactate dehydrogenase (LDH), extent of 
shape change (ESC), hypotonic shock response (HSR), morphology, and P- selectin were 
performed after storage of the products for 5 and 7 days. Of these secondary endpoints, only 
ESC, HSR, morphology, and P- selectin had established acceptance criteria. Morphology met the 
established acceptance criteria but ESC, HSR , and P- selectin values did not. The results from this 
study of Trima Accel collected platelets stored in InterSol are consistent with results of similar 
studies evaluating Amicus collected platelets stored in InterSol.6,7 
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 18 of 46 5 RATIONALE FOR THE CURRENT STUDY  
This is a prospective, open -label, multicenter , controlled study to evaluate the in vivo platelet  
recovery and survival of hyperconcentrated platelets coll ected on the Trima Accel system and 
stored for 5 days in InterSol. In order to promote better standardization among the industry for 
determining the safety and effectiveness of different platelets products (ie, different collection 
methods, different processing procedures, and/or different storage conditions), the FDA has 
issued guidance outlining the appropriate study design for in vivo platelet evaluation.8 This 
guidance recommends the radiolabeling of both st ored (Test) and fresh (C ontrol) platelets and 
their autologous reinfusion for the determination of recovery and survival.8 Using these 
recommendations, the Biomedical Excellence for Safer Transfusion  (BEST) Collaborative 
generated a platelet radiolabeling protocol that provides a detailed procedure  for the generation, 
infusion, timing of blood draws, and calculations needed to determine the platelet recovery and survival of new platelet products.
9  
Using the BEST Collaborative protocol, this study will determine the recovery and survival of 5 day platelets stored in 65% InterSol/35% plasma. Specifically, a single hyperconcentrated 
platelet unit will be collected on the Trima Accel system, diluted with 65% InterSol/35% plasma,  
and stored at room temperature with agitation for 5 days (Test). On Study Day 5, the T est 
platelets will be radiolabeled with either Indium 111 (
111In) or Chromium 51 (51Cr) according to 
a predetermined randomization scheme and their recovery and survival will be compared to fresh 
platelets (Control) radiolabeled with the other radio isotope (111In or 51Cr).  The recovery and 
survival of Test platelets will be calculated at each site according to the COST software.  
6 OBJE CTIVE 
The primary objective of this study is to determine the  in vivo recovery and survival of 
radiolabeled platelets collected on  the Trima Accel s ystem, dilut ed in InterSol , and stored for 
5 days. 
7 EFFICACY ENDPOINTS  
7.1 Primary Efficacy Endpoint s 
The primary  endpoint for this study will be the  recovery and survival of platelets as calculated 
using the COST software. Recovery (at 24 hours) is expressed as a percentage of the extrapolated platelet count at time 0. Survival is expressed in hours and is approximated using 
linear regression . 
1. In vivo radiolabeled platelet recovery > 66% 
2. In vivo radiolabeled platelet survival > 58%  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 19 of 46 For each endpoint, paired differences within each participant  will be used to construct the lower 
limit of a 1-sided 97.5% confidence interval. If the lower limit is greater than 0 for both 
endpoints, the test product will be declared to meet the FDA criteria . 
8 SAFETY ENDPOINTS  
Safety will be monitored through the collection of adverse events (AEs), serious adverse events 
(SAEs), and unanti cipated adverse device effects (UADEs) from the start of the apheresis 
procedure venipuncture until study completion.  
9 INVESTIGATIONAL PLAN  
9.1 Study Design  
This is a prospective, open- label, multicenter , controlled study to determine the in vivo recovery 
and survival of radiolabeled hyperconcentrated  platelet s collected on the Trima Accel system and 
stored for 5 days  in 65% InterSol/35% plasma. An outline of the full study design is provided in 
Figure 9-1. 
,QWHU6RO,Q9LYR3ODWHOHW4XDOLW\6WXG\  7HUXPR%&7,QF 
&OLQLFDO,QYHVWLJDWLRQ3ODQ&76  9HUVLRQ -8/
&RQILGHQWLDO  3DJHRI)LJXUH6WXG\'HVLJQ

8SWRSDUWLFLSDQWVZLOOEHHQUROOHGWRHQVXUHHYDOXDEOHFROOHFWLRQVDFURVVL QYHVWLJDWLRQDO
VLWHV$QHYDOXDEOHFROOHFWLRQLVGHILQHGDVWKHSDUWLFLSDQWFRPSOHWLQJWKHUHFRYHU\DQGVXUYLYDO
SURFHGXUHDQG QHLWKHUWKH SDUWLFLSDQW RUWKHSURGXFWPHHW LQJDQ\RIWKH&OLQLFDO,QYHVWLJDWLRQ
3ODQ&,3 DQDO\VLVH[FOXVLRQFULWHULDRXWOLQHGLQ6HFWLRQ 
7ZRVHWVRISODWHOHWVZLOOEHFROOHFWHGIURPHDFKSDUWLFLSDQW 
x$7HVWXQLW$K\SHUFRQFHQWUDWHGSODWHOHWSURGXFWFROOHFWHGRQWKH7ULPD$FFHOV\VWHPDQG
GLOXWHGWRDILQDOUDWLRRI,QWHU6ROSODVPDWKURXJKWKHDGGLWLRQRI,QWHU6ROGLUHFWO\
WRWKHSODWHOHWEDJE\WKH7ULPD$FFHOV\VWHPDIWHUFROOHFWLRQ
x$&RQWUROVDPSOH )UHVKSODWHOHWVSUHSDUHGIURPD ZKROHEORRGVDPSOHGUDZQIURPWKHVDPH
GRQRURQ6WXG\'D\LQDFFRUGDQFHZLWKWKH%(67&ROODERUDWLYH
$IWHUGRQDWLRQRID7HVWXQLWV WXG\SDUWLFLSDQWVZLOOUHWXUQ WRWKHVLWHRQ6WXG\'D\WREHJLQWKH
UDGLRODEHOHGUHFRYHU\DQGVXUYLYDOSURFHGXUH7HVWDQG&RQWUROSODWHOHWVSUHSDUHGIURPDZKROH
EORRGVDPSOHFROOHFWHG WKDWGD\ZLOOEHSUHSDUHGDQGUDGLRODEHOHG ZLWKHLWKHU,QRU&U
IROORZLQJWKHODEHOLQJDQGZDVKLQJSURFHGXUHVRXWOLQHGE\WKH%(67&ROODERUDWLYH7KHFKRLFH
RIWKHUDGLRLVRWRSHXVHGZLOOEHUDQGRPO\GHWHUPLQHGIRUHDFKSDUWLFLS DQWEDVHGRQD

InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 21 of 46 randomization scheme provided to each site from the Sponsor. After infusion with the 
radiolabeled Test and Control platelets,  blood samples for radioactivity measurements and the 
calculations to determine platelet recovery and survival will be conducted by the sites as outlined 
in the BEST Collaborative.9 Recovery and survival will be calculated at each site according to 
the COST software . 
9.2 Study Duration  
Study participation will be up to 9 vis its. Screening may be done within 5 days prior to the 
apheresis procedure or combined as 1 visit, which includes screening and the apheresis  
procedure all in 1 day. The apheresis procedure can last from 25 to 150 minutes, depending on 
the machine configuration, participant parameters, the quality of the vascular access, and the 
tolerance of the participant to the Anticoagulant Citrate Dextrose, Solution A ( ACD-A) .  
After the apheresis collection, participants will be asked to return to the site 5 days later  for the 
collection of fresh  (Control) platelets and to be infused with an aliquot of t he radiolabeled Test 
and Control platelets . Participants will then return to the site for whole blood sample collections 
as described in Section 11.  
The entire study i s anticipated to last  approximately 5 months. 
10 STUDY POPULATION  
10.1 Number of Participants  and Selection 
Assuming an approximate 40% screen fail/early termination  rate, up to 40 healthy adult 
participants will be enro lled in this study to ensure 24 evaluable data points across 
2 investigational s ites in the United States .  
Donors will be selected from the community donor and/or research pool and will be 
representative of the healthy adult volunteer population. Participants  will be recruited in a 
non-coercive manner and recruitment will be irrespective of ethnicity or gender . 
10.2 Inclusion Criteria  
1. Age 18 years or older 
2. Normal health status as per  AABB criteria for a healthy donor 
3. Able to commit to the study schedule 
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 22 of 46 4. Meets the inclusion criteria defined by the Blood Center for an apheresis platelet with 
PAS collection on the Trima Accel system. These criteria are based on FDA Regulations 
and AABB standards. Note: Participants who are deferred from volunteer community 
donations because of travel restrictions, piercings, or tattoos may participate in the study, as products are not transfused  
5. Participant s of child- bearing potential (either male or female) must agree to use an 
effective method of contraception during the course of the study  
6. Female of childbearing potential must be willing to take a pregnancy test prior to infusion of radiolabeled platelets  
7. Has given written informed consent 
8. Participant s must agree to refrain  from using aspi rin or aspirin  containing medications, 
non steroidal anti inflammatory drugs (NSAID s), anti- plate let agents, or other drugs 
affecting platelet viability for the duration of the study 
10.3 Exclusion Criteria  
1. Previously received radiation therapy  
2. Has been diagnosed with a platelet disorder (ie, platelet dysfunction) 
3. Already participated in 4 research studies  involving radioisotopes within the 
contemporaneous calendar -year 
4. Pregnant or nursing females 
5. Participation currently, or within the last 12 months, in another investigational trial that would potentially interfere with the analysis of this investigation  
6. History of known hypersensitivity to indium or chromium 
7. Treatment with aspirin or aspirin containing  medications within 7 days of apheresis or treatment with NSAID s, anti- platelet agents or other drugs affecting platelet viability 
within 3 days of apheresis (eg, ibuprofen or other NSAIDs) 
10.4 Enrollment  
A donor is considered to be an enrolled participant following inform ed consent. It is expected 
that due to the screening and eligibility requirements, some fraction of participant s will not 
qualify for a platelet donation after consent and some who are enrolled may not complete all of 
their anticipated procedures. Participants  will be considered screen failures if they fail to meet 
any of the eligibility criteria  after signing informed consent. P articipants  who do not have a 
complete donation (donor receives rinseback, there was automated addition of PAS, and final 
platelet product has a platelet yield  â‰¥ 3.0 Ã— 1011 and â‰¤ 5.1 Ã— 1011)  or do not return for the 
recovery and survival sample collections per BEST Collaborative will be considered an early 
termination.  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 23 of 46 After informed consent has been obtained, participants will receive a unique study identification  
(USID)  number . The USID number will use the following convention: XX- YYY , where XX is 
the pre- assigned site number and YYY will be a sequential number starting with 001. The USID 
number will be  recorded  on the electronic Case Report Form ( eCRF) .   
Participants  that fail screening criteria on information or laboratory values that are anticipated to 
change, may be rescreened. Participants that are an early termination or donate d a product that 
meets any of the protocol analysis exclusions (Section 16.4) may rescreen as long as they were 
not infused with a radiolabeled  product and will meet all the inclusion criteria when they return. 
Participants that are rescreened will be assigned a new USID number. 
11 STUDY PROCEDURES  
A summary of study procedures is provided in Table 11-1. 
  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 24 of 46 Table 11-1: List of Study Procedures  
 Screening  
Visit  
 (Day -5 â€“ Day 0)  Apheresis 
Visit  
(Day 0) Post 
Collection 
(Day 0 â€“ 5) Infusion Day  
 (Study Day 5 
or BEST Day 0)  Post-Infusion Days  
(Study Days 6- 17 or 
BEST Day s 1-12)a 
Obtain informed c onsent  X     
Confirm e ligibility  X     
Collect demographics (date of birth , gender, race, ethnic origin), 
height, and weight  X     
Record  relevant  medical history  X     
Confirm participant is healthy    X  X  
Record any medications taken in the  7 days prior to apheresis 
procedure and through study completion  X  X X 
Confirm participant did not take any exclusionary medicationb  X  X X 
Fingerstick for Hgb or HCT   X    
Conduct apheresis procedure per Trima Accel Operatorâ€™s Manual   X    
Collect venous whole blood sample from diversion pouch  and 
conduct CBC in duplicatec  X    
Update Trima Accel machine with the averaged CBC results   X    
Record serial numbers, lots , and expiry dates of equipment, 
disposables , and solutionsd  X    
Record Trima End Run Summary Report detailse  X    
Conduct CBC on platelet productf  X    
Label productg    X   
Store at 20Â°C  Ì¶  24Â°C with agitation away from normal blood 
inventory    X   
Conduct bacterial testing on stored platelet producth   X   
Conduct pregnancy test for women of child bearing potential (serum 
or urine)     X  
Test stored  platelet product pHi    X  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 25 of 46  Screening  
Visit  
 (Day -5 â€“ Day 0) Apheresis 
Visit  
(Day 0) Post 
Collection 
(Day 0 â€“ 5) Infusion Day  
 (Study Day 5 
or BEST Day 0)  Post-Infusion Days  
(Study Days 6- 17 or 
BEST Day s 1-12)a 
Collect whole blood sample and generate Control  platelets according 
to BEST     X  
Radiolabel Test and Control platelets according to BEST     X  
Record vital signsj    X  
Infuse radiolabeled  autologous  platelets (Test and Control ) 
according to BEST     X  
Collect 5 -10 mL of whole blood into an EDTA tube for radiation 
counting    Xk X 
Conduct radiation counting per BEST protocol     X X 
Record AE, SAEs, or UADEs   X  X X 
Record medical interventions  to treat AEs  or SAEs   X  X X 
Review AEs/SAEs since previous visit, if applicable     X X 
Record device deficiencies   X  X  
a Post- infusion visits will occur daily (except on weekends) from Study Day 6 through Study Day 12 (BEST Day 1 -7). Additionally, 1 final visit will occur on 
Study Day 15, 16, or 17 (Best Day 10, 11, or 12).  
b Exclusionary medication includes aspirin or aspirin containin g medications, NSAIDs, anti -platelet agent s, or other drugs affecting platelet viability.  
c After venipuncture , a CBC will be done in duplicate for Hgb or HCT and platelet count. These averaged values will be used to update the Trima Accel 
machine.  
d Record Trima Accel machine serial number and lot number and expiration date of the disposable set, ACD- A, PAS adaptor, and InterSol used.  
e Record end run time, platelet volume, platelet yield, PAS volume added, and Trima flags  that result in study discontinuation  per Section 11.6.  
f Confirm platelet yield is â‰¥ 3.0 Ã— 1011 and â‰¤ 5.1 Ã— 1011 total platelets and platelet product concentration is 0.7 to 2.1 Ã— 106/ÂµL. 
g Label â€œFor Investigational Use Onlyâ€ and with USID number.  
h Bacterial testing conducted per site standard operating procedures with results confirmed on Study Day 5.  
i Confirm pH â‰¥ 6.2.  
j Vital signs taken prior to preinfusion sample collection and to include blood pressure, heart rate, and temperature.  
k Blood samples will be drawn pre -infusion and 2 hours Â± 15 minutes after infusion.  
Abbreviations: AE = adverse event; BEST = Biomedical Excellence for Safer Transfusion  Collaboration; CBC = complete blood count; 
EDTA  = ethylenediaminetetraacetic acid; HCT = hematocrit; Hgb = hemoglobin; NSAID = non -steroidal anti inflammatory drug; PAS = platelet additive 
solution; SAE = serious adverse event; UADE  = unanticipated adverse device effect ; USID = unique subject identification.  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 26 of 46 11.1 Screening Visit: Study Days -5 to 0 
Screening can be performed within 5 days before the apheresis procedure or combined with the 
Apheresis Visit.  
The following evaluations will be performed: 
1. Obtain informed consent prior to initiating any study specific procedures 
2. Confirm e ligibility  
3. Collect d emographics ( date of birth , gender, race, eth nic origin), height,  and weight  
4. Record relevant medical history  
11.2 Apheresis Visit: Study Day 0 
The following procedures will be performed during the apheresis v isit. 
11.2.1 Prior to Apheresis  
1. Confirm participant is healthy  
2. Record any medications taken in the  7 days prior to the  Apheresis Visit and during this 
visit  
3. Confirm the participant did not take any excludable medication ( see Section 13) if 
screening visit was p rior to apheresis visit 
4. Finger stick for Hgb or HCT testing 
11.2.2 Apheresis Procedure 
Apheresis procedures will be run according to the instructions and precautions described in the commercially available Trima Accel Operatorâ€™s Manual.  The procedure selection pr ocess 
(platelet yield, volume, and concentration) will be conducted per the siteâ€™s standard practice for a 
single platelet donation. 
The following procedures will be performed: 
1. Venipuncture 
2. Collect venous whole blood sample from the diversion pouch 
a. Conduct a complete blood count (CBC) in duplicate for Hgb or HCT and platelet 
count 
3. Update Trima Accel device with updated averaged platelet count and Hgb or HCT 
4. Perform  apheresis procedure for a single hyperconcentrated platelet product  
5. Record the following: 
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 27 of 46 a. Trima Accel machine serial number and lot number and expiration date of disposable 
set, ACD-A, PAS adaptor, and InterSol used 
b. Trima End Run Summary Report details  
i. End run time, platelet volume, platelet yield,  PAS volume added, and Trima flags 
that re sult in study discontinuation per Section 11.6 
c. AEs, SAEs , and UADEs  starting from the time of venipuncture  
d. Medical interv entions to treat AEs or SAEs  
e. Device deficiencies  
6. Conduct CBC on collected platelet product to confirm platelet yield and concentration conform to Trima Accel platelet storage bag specifications  
a. Record platelet yield and confirm platelets yield is â‰¥ 3.0 Ã— 10
11  and â‰¤ 5.1 Ã— 1011  
b. Record platelet concentration and confirm it is within 0.7 to 2.1 Ã— 106/ÂµL 
11.3 Post Collection Handling : Study Days 0  - 5  
Blood products collected in this study will be labeled â€˜For Investigational Use O nlyâ€™ and with the 
USID number and will be stored segregated from the siteâ€™s normal blood product inventory.  
The Test platelet units will be stored at 20ÂºC  Ì¶  24ÂºC with agitation for 5 days. Platelets will be 
tested for bacterial testing per the siteâ€™s SOP and all products that are negative will be used. Any 
product that is positive will be destroyed per the siteâ€™s SOPs and will not be radiolabeled or 
infused into the participant.  
11.4 Infusion Day: Study Day 5 (BEST Day 0) 
Five (5 ) days  after a study  participant has donated a Test product, they will return for the 
donation of fresh Control platelets, reinfusion of Test and Control platelets, and post-infusion 
sampling. Study Day 5 corresponds to the Infusion Day/Day 0  in BEST.  
The following procedures will be conducted:  
1. Confirm participant is healthy and did not take any excludable medication 
2. Record any concomitant medications taken since previous visit and during this visit 
3. Conduct pregnancy test for women of childbearing potential (serum or urine) 
4. Test pH of the Test platelet product to confirm product meets FDA specifications (pH â‰¥ 6.2) 
5. Review AE s/SAEs since previous visit , if applicable 
6. Collect  a whole blood sample per BEST procedures for  the production of Control 
platelets   
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 28 of 46 7. Radiolabel Test and Control platelets according to BEST 
When the combined injectate is ready for infusion, the followi ng procedures will take place:  
1. Record vital signs (blood pressure, heart rate, temperature) prior to preinfusion sample 
collection  
2. Infuse radiolabeled  autologous combined Test  and Control platelets into participantâ€™s 
vein per BEST  procedure 
3. Collect a 5 -10 mL sample into an EDTA tube for pre - and post- infusion testing using the 
opposite arm as for  the infusion 
a. Prior to infusion 
b. 2 hours Â± 15 minutes post-infusion 
4. Record AEs , SAEs , or UADEs  
5. Record medical interventions used  to treat AEs or SAEs  
6. Record device deficiencies 
7. Conduct radiation counting per BEST protocol 
11.5 Post-Infusion Days  
11.5.1 Study Days 6-12 (BEST Days 1 -7) 
The participant will return to the investigation site daily  (except on weekends) between  
Study Day 6 and Study Day 12 ( BEST D ay 1 through Day 7 ). A total of 5 samples are req uired 
to be collected in this 7 day period in order for the participantâ€™s data to be evaluable  for primary 
endpoint analysis, per BEST.  
The participant procedures at each of these visits are as follows: 
1. Confirm participant did not take any exclusionary medication  since previous visit (see 
Section 13 ) 
2. Record any concomitant medications taken since previous visit an d during these visits   
3. Collect a 5 -10 mL sample into an EDTA tube to measure radioactivity  
4. Conduct radiation counting per BEST protocol 
5. Record AEs , SAEs  or UADEs  experienced since previous visit and during visit 
6. Record  medical interventions  to treat AEs or  SAEs  
11.5.2 Study Day 16 Â± 1 day (BEST Day  11 Â± 1 day) 
The participant will return to the investigation site for 1 final sample on  Study Day 15, 16, or 17 
which corresponds to BEST Day 10, 11, or 12. 
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 29 of 46 The p articipant procedures at each of these visits are as follows :  
1. Confirm participant did not take any exclusionary medication  since previous visit (see 
Section 13 ) 
2. Record any concomitant medications taken since previous visit and during this visit 
3. Collect a 5 -10 mL sample into an EDTA tube to measure radioactivity  
4. Record AEs , SAEs , or UADEs  experienced  since previous visit and during visit  
5. Record medical interventions  to treat AEs or SAEs  
11.6 Study Procedure Discontinuation/Termination  
All participants  are free to withdraw from the study at any time, for any reason, specified and 
unspecified, and without prejudice. The reason for the participant discontinuing study treatment 
or terminating from the study will be recorded on the Source Documents (SD) and e CRF. 
Reasons for study termination may include: 
1. Development of an AE that interferes with the participantâ€™s continued participation 
2. Participant  refuses further treatment and/or follow -up and withdraws consent 
3. Device deficiency or protocol deviation that ends the apheresis procedure early  
4. Inability to collect a complete platelet unit  
5. Procedure that produces a product quality Trima flag that results in the Test platelet 
product having insufficient yield, insufficient leukoreduction, or insufficient additive 
solution delivery 
6. Incomplete or incorrect post-collection processing due to equipment failure or malfunction (eg, under-delivery of PAS due to unrecoverable system failure or 
malfunctioning sterile barrier filter)  
7. Solution other than InterSol added to platelets prior to storage  
8. The collected platelet product falls outside of the Trima Accel platelet product storage 
boundaries: 
a. < 3.0 Ã— 10
11 or > 5 .1 Ã— 1011 total platelets  
b. Platelet product concentrations outside of 0.7 to 2.1 Ã— 106/ÂµL  
9. Product damaged during storage 
10. Positive pregnancy test 
11. Positive bacterial test 
12. pH of Test product < 6.2 
13. Investigator decision  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 30 of 46 14. Sponsor decision 
15. Participant  is lost to follow-up or does not complete at least 5 of  the post-infusion blood 
sampling for recovery and survival calculations 
16. Participant  death  
17. Participant took exclusionary medication (see Section 13) 
11.7 Stopping Rules  
There are no pre-specified stopping rules for this study . The Sponsor may stop the study for any 
reason.  
12 LABORATORY TESTS  
12.1 Clinical Laboratory Tests 
The clinical laboratory tests for the participant â€™s finger stick, the CBC (run in duplicate) for the 
Trima Accel update, and the pregnancy test on childbearing females prior to infusion of 
radiolabeled platelets will be analyzed locally at each study site. Copies of the current laboratory 
certifications and normal ranges will be provided to the Sponsor prior to start of the study and 
upon every renewal throughout the duration of the study. 
12.2 Test Product Laboratory Test 
The Test platelet product will have a CBC conducted on Day 0 per Section 11.2.2, bacterial 
contamination testing conducted between Study Day 0 and Study Day 5 per siteâ€™s SOPs per Section 11.3, and pH testing conducted on Day 5 per Section 11.4.  
12.3 Platelet Radiolabeling Procedures 
Radiolabeling of Test and Control platelets , the subsequent testing of participant blood samples 
for the primary endpoint analysis, and the calculations to determine the platelet recovery and 
survival will be conducted locally at each study site as outlined by the BEST collaborative in 
2006 9. The recovery and survival of platelets will be calculated at each site according to the 
COST software.  
All platelet products will be destroyed per the siteâ€™s SOPs after the final sample is taken.  
13 CONCOMITANT MEDICATIONS  
Participants are prohibited from taking aspirin or aspirin containing medications for 7 days prior 
to the apheresis procedure, and NSAIDs, anti- platelet agents, or other drug s affecting platelet 
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 31 of 46 viability  for 3 days prior to the apheresis proce dure.  Once enrolled in the study, participants are 
prohibited from taking these medications throughout their participation in the study.   
Concomitant medications taken from the 7 days before the apheresis visit  until study exit will be 
recorded in the eCRFs. 
Medical interventions administered to treat AEs or SAEs will be recorded in the eCRFs.  
14 ADVERSE EVENTS/EFFECTS  
14.1 Anticipated Risks  
14.1.1 Venipuncture Related  
The risks associated with venipuncture for blood sampling or intravenous ( IV) access include 
apprehension, pain, discomfort, venospasm, fainting, bruising, infiltration at the venipuncture 
site, clotting in the IV tubing, and/or administrative errors. Occurrence rates of venipuncture AEs 
are summarized in Table 14-1. 
Table 14-1: Venipuncture Adverse Event Frequency  
Location  Very Common  
â‰¥ 1/10 Common  
â‰¥ 1/100 to  
< 1/10 Uncommon  
â‰¥ 1/1,000 to  
< 1/100  Rare  
â‰¥ 1/10,000 
to < 1/1,000  Very rare  
< 1/10,000  Not known  
Sporadic case 
reports  
General10-12 Apprehension 
 Presyncopea 
 Faintb    
At puncture 
site11-14  Hematoma   Nerve irritation  Arterial puncture   
Pain Infection  
Distant of 
puncture 
site11,12,14  Discomfort    Skin allergy  Phlebitis  
Neuropathic pain
 
 DVT  
Abbreviations: DVT = deep vein thrombosis  
a Presyncope includes symptoms such as pallor, lightheadedness, dizziness, nausea, diaphoresis.  
b Faint defined as a brief loss of consciousness, usually less than 30 seconds.  
14.1.2 Apheresis Complications in Healthy Donors  
Donor reactions are mostl y transient self -limited events  and in very rare exceptions a donor may 
experience long- term morbidity or sustain permanent impairment.11,14 Small hematomas, 
presyncopal episodes, and citrate reactions account for the majority of complications in 
automated collection procedures, and younger or first- time donors are more likely to experience 
complications.11-14 Although rare (< 5 out of 10,000 apheresis donations), almost 40% of 
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 32 of 46 reactions requiring medical care outside the donation premises are venipuncture related, 
including large hematoma, and possible nerve irritation.14 
Apheresis donation is reasonably safe and the majority of complications are mild in nature. While definitions on severity differ in the literature, commonly used paramet ers to assess 
severity are the necessity for outside medical care, recovery time, and potential life-threatening 
consequences. Mild reactions consist of signs and symptoms with a normal recovery time (within 
14 min). Moderate reactions usually require medical care and/or have a prolonged recovery time 
(within 30 min), and severe reactions comprise life- threatening risks and/or recovery time goes 
beyond 30 min.
11,13- 15  Mild citrate reactions are very common with apheresis procedures, while 
vasovagal reactions are substantially lower compared to whole blood donation.12-14 Some donor 
reactions that have been previous ly reported for automated collection procedures are anxiety, 
chills, digit and/or facial paresthesia, fever, headache, hematoma, hyperventilation, hypotension, 
light-headedness, nausea and vomiting, fainting, unpleasant taste sensations, urtica ria, and 
allergic reacti ons. Adve rse reactions listed in Table 14-2 are general apheresis risks and are not 
specific to the Trima Accel system . 
Table 14-2: Apheresis Adverse Event Frequency  
Event type  Very 
Common  
â‰¥ 1/10 Common  
â‰¥ 1/100 to  
< 1/10 Uncommon  
â‰¥ 1/1,000 to  
< 1/100  Rare  
â‰¥ 1/10,000 to 
< 1/1,000 Very rare  
< 1/10,000  Not known  
Sporadic case 
reports  
Citrate 
Reactions13,14,1
6,17 
 Paresthesia  Nausea  Vomiting  Tetany  Arrhythmia  Cardiac arres t 
Lightheadednes s Cramps  Seizure  
Metallic taste Spasms  
Chills  
Vasovagal 
Reactionsa 12-
14,17 
  Presyncop eb Vomiting  Convulsion  LOC with trauma injury   
Weakness  Hypotension  Seizure  
Syncope  Bradycardia  
Other Notable 
Events12-14,17      Respiratory distress  
Circulatory collapse  
Anaphylactic reaction  
Hemolysis  
Air emboli  
Death  
Abbreviations: LOC = l oss of consciousness  
a Some events might be contributed to accidental (due to disposable/equipment failure causing additional blood loss) 
hypovolemia instead of a vasovagal reaction.  
b Presyncope includes symptoms such as pallor, lightheadedness, dizziness, nausea, diaphoresis.  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 33 of 46 14.1.3 Apheresis Risks with the Trima Accel System  
Trima Accel disposable tubing sets are sterilized with ethylene oxide which may cause 
anaphylactic reactions. Though cases of allergic reactions to ethylene oxide are reported in 
literature, the Sponsor has no knowledge that any such event has occurred with the Trima Accel 
system  to date. 
14.1.4 Potential Risks of Infusion of Radiolabeled Platelets  
The amount of radiation exposure received by the participant  is low and is not considered to be a 
health hazard .18 However, women who are pregnant or who are nursing will be excluded from 
the study, as the risks of radiation exposure to a fetus or infant are unknown. All enrolled women 
will have a pregnancy test performed before the re -infusion of the radiolabeled  platelets as an 
added precaution. Any participant  with a positive pregnancy test will be withdrawn from the 
study. 
14.2 Risk Mitigation  
To minimize risks of participant  injury, the following general procedures are to be followed: 
1. Ensuring that all Investigators are properly qualified and meet pre- specified criteria for 
Investigator selection and that they and their study teams successfully complete the 
following training: Site specific training, Human Participant  Protection, and C linical 
Investigation Plan ( CIP) training to include device and procedure training.  
2. Ensuring that participants who are enrolled meet all eligibility criteria, including 
minimum Hgb or HCT  and platelet limits for donation. The apheresis devices are 
programmed to allow collection of products only from participants  who will meet 
projected HCT /Hgb  and platelet standards at the completion of the collection. These 
limitations are for the safety of participants and apply to this CIP . 
3. If the Investigator deems appropriate, stopping the procedure if a moderate or severe AE 
occurs . The participant  can also request that the procedure be stopped at any time.  
4. With the collection of protected health information (PHI) associated with this research 
study, there is a small risk of violation of privacy and loss of confidentiality. The 
apheresis collections will be documented on the study s iteâ€™s SD. Case report forms will 
be uploaded to the electronic data capture ( EDC) with only participant  and product 
number as participant  identifiers, to ensure confidentiality.  
5. Participants  will be questioned concerning adverse experiences throughout the apheresis 
procedure. Participants  will also be visually monitored for signs of distress during blood 
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 34 of 46 donations . Suspected adverse reactions will be treated according to study sitesâ€™ SOPs and 
documented on the SD and e CRFs.  
14.3 Adverse Event Definitions  
An AE is defined as any untoward medical occurrence in a clinical investigation participant, 
temporally associated with the use of a medical device, whether or not considered related to the 
medical device and/or procedure. Therefore, an AE can be any unfavorable and unintended sign 
(inclu ding an abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of the medical device and/or procedure. 
14.4 Adverse Event Recording  
Adverse events that occur after the start of the apheresis procedure venipuncture until study 
completion will be recorded on the AE e CRF.  
14.5 Adverse Event Reporting  
14.5.1 Severity  
This study will utilize the Common Terminology Criteria for Adverse Events [CTCAE] Scale, 
Version 4.03 for AE grading.19 The CTCAE includes a grading (severity) scale for each AE term. 
Grades were developed using the following guidelines: 
Grade 0  â€“ No AE or within normal limits.  
Grade 1  â€“ Mild; asymptomatic or mild symptoms; clinical or diagnostic observations 
only; interve ntion not indicated. 
Grade 2  â€“ Moderate; minimal, local or noninvasive intervention indicated. 
Grade 3  â€“ Severe; medically significant but not immediately life threatening . 
Grade 4  â€“ Life threatening. 
Grade 5  â€“ Fatal.  
14.5.2 Relationship  
The Investigator at each site will be asked to document his/her opinion of the relationship of the 
event to the device and/or procedure(s) as follows:  
Not Related: 
The event is clearly related to factors other than the study device and/or procedure(s), such as the 
participant â€™s clinical state.  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 35 of 46 Possibly Related:  
The event follows a reasonable temporal sequence from the time of study treatment 
administration/ procedure, and/or follows a known response pattern to study device/procedure(s) 
but could have been produced by other factors , such as the participant â€™s clinical state or other 
therapeutic interventions.  
Probably Related:  
The event follows a reasonable temporal sequence from the time of study device /procedure(s) 
and cannot be reasonable explained by other factors, such as the participantâ€™s clinical state or 
therapeutic interventions.  
Definitely Related:  
The event follows a reasonable temporal sequence from the time of study device/procedure(s), 
and follows a known response pattern, and cannot be reasonably explained by other fact ors. In 
addition, the event occurs immediately following study procedure(s), and/or improves on stopping the study procedure, and/or re appears on resumption of study procedure(s). 
These criteria, in addition to good clinical judgment, should be used as a guide for determining the causal assessment . 
14.6 Adverse Event Follow -up 
All AEs must be followed in accordance with the International Conference of Harmonization (ICH) Good Clinical Practice (GCP) guidelines, and other applicable regulatory requirements 
(eg, United S tates Code of Federal Regulations [CFR] 812). The expected AE of mild hematoma 
(bruise) and/or mild infiltration are not required to be followed to resolution.  
14.7 Serious Adverse Events and Unanticipated Adverse Devi ce Effect  
14.7.1 Definition  
In the interes t of participant  care and to allow the Sponsor to fulfill all regulatory requirements, 
any SAE and/or UADE, regardless of causal relationship to study treatment/procedure(s), must be reported to the Sponsor within 24 hours of knowledge of the event. 
Seriou s AEs are defined (21 CFR 312.32 and ISO 14145:2011 Sec. 3.37) as those AEs which 
meet any of the following criteria:  
â€¢ Results in death .  
â€¢ Led to serious deterioration in the health of the participant , that either resulted in  
o A life -threatening illness or injury, or  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 36 of 46 o A permanent impairment of a body structure or a body function, or  
o Inpatient or prolonged hospitalization, or  
o Medical or surgical intervention to prevent life -threatening illness or injury or 
permanent impairment to a body structure or a body function. 
â€¢ Led to fetal distress, fetal death or a congenital abnormality or birth defect.  
NOTE: Planned hospitalization for a pre-existing condition or a planned procedure, without 
serious deterioration in health, is not considered a n SAE . 
Per 21 CFR 812.3 an UADE is defined as any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with a device, if that effect, problem or 
death was not previously identified in nature, severity, or degree of incidence in the CIP  and/o r 
Trima Accel Operatorâ€™ s Manual, or any other unanticipated serious problem associated with a 
device that relates to the rights, safety, or welfare of participants . 
NOTE: Anticipated adverse device effects are effects, which by nature, incidence, severity or outcome have been identified in the CIP and/or Trima Accel Operatorâ€™ s Manual. 
14.7.2 SAE/UA DE Reporting  
Any SAE/UADE that occurs after the start of the apheresis procedure venipuncture until study 
completion/termination must be reported. Follow-up (regardless of relationship to the study 
treatment/procedure[s]) must be reported and an AE/SAE/UADE Form must be submitted to the 
Sponsor within 24 hours of knowledge of the event to: 
Terumo BCT  
Email: ClinicalAffairs@TerumoBCT.com   
Fax: (303) 876-9146 
The Sponsor may request additional information from the I nvestigator to ensure the timely 
completion of accurate safety reports.  
Additionally the SAE/UADE must be entered on the AE page(s) of the eCRF. Follow-up 
SAE/UADE reports need to be submitted to the Sponsor as soon as additional information 
regarding the event becomes available.  
The Sponsor will be responsible for reporting S AE/UADEs to the regulatory authorities in 
accordance with applicable regulatory reporting guidelines. The I nvestigator is responsible for 
submitting SAE/UADEs to his/her Institutional Review Board (IRB) as required by local policy.  
Exclusions to SAE/UADE R eporting Requirements  
The following are not considered SAEs/UADEs: 
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 37 of 46 â€¢ Planned hospitalization 
â€¢ Anticipated day- to-day fluctuations of pre-existing condition(s) present or detected at the 
start of the study that do not worsen 
14.8 Clinical Investigation Plan Deviations  
A CIP deviation is defined as any event where the Investigator or site personnel deviate from the 
study CIP or study procedures for any reason. 
The Sponsors is responsible for report ing all deviations into the EDC. Clinical Investigation Plan  
deviations that may affect the scientific soundness of the study or affect the rights, safety, or 
welfare of study participants , must be reported to the Sponsor and the IRB as per the IRBâ€™s 
standard reporting procedure.  
14.9 Medical Monitoring  
It is the responsi bility of the Investigator to oversee the safety of the study at his/her site. A Data 
Safety Monitoring Board will not be involved in this study because it involves healthy participants  undergoing a commonly practiced research evaluation procedure and no 
investigational product will be transfused. 
The Sponsor will monitor the safety of the study participants  from the venipuncture for the 
apheresis procedure and until conclusion of t heir participation in the study .  
15 STUDY DEVICE 
15.1 Device Deficiencies  
All devic e deficiencies involving any device component must be reported within 24 hours upon 
knowledge to the Sponsor utilizing the Device Deficiency Report Form. Every attempt should be 
made by the s ite to save or collect the defective device, and if appropriate, the packaging, for 
return to the Sponsor. A qualified company representative will investigate and determine root cause and corrective actions as applicable, and directives will be provided to the site if 
warranted.  
15.2 Device Accountability  
15.2.1 Receipt of Study De vice 
The contents should be examined upon receipt to ensure packaging and labeling is intact and the devices have not been damaged. Any damage should be immediately reported to the Sponsor. 
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 38 of 46 15.2.2 Storage 
The Trima Accel device, the InterS ol, and the disposables should be stored in a dry place at room 
temperature. Proper care should be taken to ensure that the study inventory will not be damaged. 
15.2.3 Accountability  
The Trima Accel device, disposables, InterSol, and software will be provided by the Sponsor for 
use in this study. The Trima Accel disposables, software, and InterSol are FDA cleared and 
marketed in the United States ; however platelets collected on the Trima Accel system and stored 
in InterSol is not, therefore the site must take appropriate measures to ensu re it is properly stored  
away  from approved inventory.  
16 STATISTICAL PLAN 
16.1 Sample Size  
Assuming an approximate 40% screen fail /early termination  rate, up to 40 healthy adult 
participants will be enrolled in this study to ensure 24 evaluable data points across 
2 investigational s ites in the United States.  
Donors will be selected from the community donor and/or research pool and will be representative of the healthy adult volunteer population. Participants  will be recruited in a 
non-coercive manner and recruitment will be irrespective of ethnicity or gender.  
16.2 Outcome Measures  
This study will determine the  recovery and survival of hyperconcentrated platelets collected on 
the Trima Accel system and stored for 5 days in 65%  InterSol/35% plasma . The recovery and 
survival of Test platelets will be compared to fresh Control platelets . 
16.2.1 Primary Endpoint  
The acceptance criterion for the recovery (%) of platelets is  the demonstration of non- inferiority 
by the rejection of the Null Hypothesis (H0) defined by the following hypotheses: 
Null Hypothesis  H 0:  Âµd â‰¤ 0 where Âµd=ÂµT-0.66*ÂµC 
Alternate Hypothesis   H 1:  Âµd > 0 
Let âˆ†Xi = (X Ti-0.66*X Ci) be a difference if recovery for patient i. The sample mean and standard 
deviations of these observed differences will be used to construct the lower limit of a 1-sided 
97.5% confidence interval for Âµd assuming a t -distribution with n -1 degrees of freedom. If the 
lower limit of the confidence interv al is greater than 0, the null hypothesis will be rejected in 
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 39 of 46 favor of the alternative hypothesis suggesting the Test product meets the FDA acceptance criteria 
for platelet recovery.  
The acceptance criterion  for the survival (hours) of platelets is the dem onstration of 
non-inferiority by the rejection of the null hypothesis (H0)  defined by the following hypotheses: 
Null Hypothesis  H 0:  Âµd â‰¤ 0 where Âµd=ÂµT-0.58*ÂµC 
Alternate Hypothesis   H 1:  Âµd > 0 
Let âˆ†Xi = (X Ti-0.58*X Ci) be a difference in survival for patient i . The sample mean and standard 
deviations of these observed differences will be used to construct the lower limit of a 1-sided 
97.5% confidence interval for Âµd assuming a t -distribution with n -1 degrees of freedom. If the 
lower limit of the confidence interval is greater than 0, the null hypothesis will be rejected in  
favor of the alternative hypothesis suggesting the Test product meets the FDA acceptance criteria 
for platelet survival.  
16.2.2 Safety Measures 
Adverse even ts will be summarized by the medical dictionary for regulatory activities (MedDRA 
Version 18.1 or later) and verbatim term . Tables will describe the frequency and percentage of all 
AEs, SAEs, and UADEs reported by participants  in the safety population. Pre sentations will 
summarize AEs by maximum reported severity and relationship to device and procedure. 
Adverse events leading to study or procedure discontinuation will also be tabulated.  
16.3 Analysis Population 
The safety population will include all participants enrolled in this trial who undergo any study 
related apheresis procedure.  
The Full Analysis Set (FAS) will consist of all completed procedures/ products where the 
corresponding Test and Control values for the primary endpoint are valid. If any of the criteria 
outlined in Section 16.4 are met , the product will not be included in the FAS. The FAS will be 
used to examine the primary endpoints. 
16.4 CIP Analysis Exclusions  
Data points may be excluded from analysis in the following situations: 
1. Primary endpoint laboratory samples are lost or not available  
2. Failure  of the site  to follow post-collection handling procedures for endpoint assays  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 40 of 46 17 STUDY MANAGEMENT 
17.1 Investigator Responsibilities 
17.1.1 Investigator Agreement  
Each Investigator will provide the Sponsor a copy of his/her current curriculum vitae and a 
signed Investigator Agreement, prior to initiation of the study.  
17.1.2 Institutional Review Board  
The IRB or other committee functioning in a similar capacity  will review and approve the CIP  
and any CIP  amendments, initial and revised informed consent (IC) documents, and recruitment 
materials , if applicable . After approval by the IRB, documentation of approval and the approved 
IC document will be sent to the Sponsor before any participant is enrolled into this study.  
17.1.3 Informed Consent  
The Investigator is resp onsible for preparing the written IC document for this study. The Sponsor 
will provide the Investigator an IC template. The Investigator may rearrange or reword the 
contents of the template, or may add other elements or language, provided the meaning and 
content are not changed or deleted.  
Prior to participant  participation in this study, the I nvestigator must obtain written IRB approval 
for the CIP  and the ICF. The approved consent form will clearly reflect the IRB approval date.  
Once the participant â€™s initial eligibility has been determined, the Investigator or person 
designated by the Investigator, who has been trained on the CIP , will explain the nature and 
scope of the study, potential risks and benefits of participation, answer questions for the participant  and ask the participant  to participate in the study. The study will be explained to the 
study participant in lay terms , in their native language in a quiet, non-disruptive setting. Potential 
participants  will be given as much time and privacy as necessary to review the informed consent 
prior to agreeing to participate in the study. Additionally, if the participant  desires, they can take 
a copy of the consent with them so that they can discuss potential participation with others 
outside the study team. If the participant  agrees to participate, the participant has read the ICF, 
and has had all of their questions answered, then the ICF must be signed and personally dated by the participant and the person completing the consent process. A copy of the signed and dated 
ICF will be provided to the study participant.  
All participants  are free to withdraw from participation in this study at any time, for any 
reason (s), specified or unspecified, and without prejudice. The reason(s)  for the participant 
discontinuing or terminating from the study must be recorded on the e CRF.  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 41 of 46 17.1.4 Study Files and Record Retention  
Investigational sites will maintain all records pertaining to this study for a minimum of 2 years 
following pre-market approval or 2 years after the study is discontinued. The sponsor will notify 
investigational sites of the discontinuation. Prior to discarding any study- related records, all 
clinical sites must contact the sponsor for direction.  
17.1.5 Regulatory Compliance  
Sites are responsible for meeting  all applicable FDA regulations (eg, 21 CFR 600-680 and 
21 CFR 800) and AABB standards. Sites will be responsible for staying current on new standards and meeting any new regulations which may be implemented during the course of this study. 
17.2 Sponsor Responsibilities  
17.2.1 Amendments to the CIP 
Any amendment to the CIP , as deemed appropriate by the Sponsor , will be implemented as the 
study progresses. Amendments will be submitted to the FDA and IRB for written approval, before implementation.  
17.2.2 General Respon sibilities  
As per  International Organization for Standardization ( ISO) 14145 Section 8 and 21 CFR 812, 
Terumo BCT is responsible for selecting qualified Investigators and providing them with the 
information they need to conduct the investigation properly, ensuring quality study conduct and 
proper monitoring of the investigation, ensuring required approvals are obtained and that 
significant new information about an investigation is promptly reported to reviewing IRB and 
government authorities as well as annual reports as required.  
17.3 Joint Investigator -Sponsor Responsibilities  
17.3.1 Training  
The Sponsor will train applicable study team members as to the device, CIP, and study 
procedures and will provide updated information as it becomes available during the course of the study, if applicable. The Investigator is responsible for ensuring that additional site personnel that 
were not trained by the Sponsor receive applicable documents and training.  
17.4 Collecting and Recording Data 
The Investigators will maintain complete, accurate, legible, and easily retrievable data, and will 
allow personnel authorized by the Sponsor access to all study data at any time. Such data shall  
also be secured in order to prevent loss of data.  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 42 of 46 All required data for this study will be recorded from the source d ocumentation onto 
standardized eCRFs.  
17.4.1 Source Documents  
Source data is all information, original records of clinical observations, or othe r activities in a 
clinical trial necessary for the reconstruction and evaluation of that trial. Source data are 
contained in source documents. Examples of these original documents and data records include 
Blood Center records, evaluation checklists, and la boratory results.  
17.4.2 Case Report Forms  
The study e CRF via EDC  is the primary data collection instrument for the study. All data must be 
recorded in English. Any missing data must be explained.  
Completed eCRFs will be reviewed and signed by the Investigator. The clinical research 
associate will verify the EDC data with the participant â€™s source data, evaluate the data for 
accuracy, consistency, and completeness, and will ensure that all forms with missing data and/or 
errors are ultimately addressed. Accurate an d complete e CRFs for a participant must be 
completed in a timely manner. 
17.5 CIP Compliance  
The Investigator is responsible for ensuring the study is conducted in accordance with the 
procedures and evaluations described in this CIP.   
17.6 Termination of the Study  
For reasonable cause, either the I nvestigator or the Sponsor may terminate the Investigatorâ€™s 
participation in this study, provided a written notice is submitted within the time period provided 
for in the Clinical Trial Agreement (CTA). In addition, the Sponsor may terminate the study at 
any time upon immediate notice for any reason, including but not limited to, the Sponsorâ€™s belief that termination is necessary for the safety of participants  or failure to meet the primary 
endpoints. 
17.7 Publication Policy 
The Sponsor recognizes the importance of communication of medical study data, and encourages 
the publication of such data in reputable scientific journals and the presentation of such data at scientific seminars and conferences. Any proposed publication or pre sentation of the data 
generated from the study must be provided to the Sponsor for timely review in accordance with the terms of the CTA between the Investigator, the Institution, and the Sponsor . The Sponsor 
shall not, in its scientific publications or promotional material, quote from publications by 
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 43 of 46 Investigators without full acknowledgment of the source. As this will be a multi- site study, all 
Investigators agree not to publish individual site data. All study data will be published as 1 or 
more manuscrip ts based on the accumulated data from all study sites.  
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 44 of 46 18 REFERENCES  
1. Alhumaidan H, Sweeney J. Current status of additive solutions for platelets. J Clin 
Apher. 2012;27(2):93- 98. 
2. Holme S, Heaton WA, Whitley P. Platelet storage lesions in second-generation 
containers: correlation with in vivo behavior with storage up to 14 days. Vox Sang. 
1990;59(1):12-18. 
3. Slichter SJ, Corson J, Jones MK, et al. Exploratory studies of extended storage of 
apheresis platelets in a platelet additive solution (PAS). Blood. 2014;123(2):271-280. 
4. Fenwal. InterSol Solutio n: Platelet Additive Solution 3. 2009. 
5. CBER. Guidance for Industry and FDA Review Staff: Collection of Platelets by 
Automated Methods. 2007. 
6. TerumoBCT. CTS- 5051: In Vitro Study of Platelets Collected on Trima Accel System 
and Stored in InterSol Solution. 2016. 
7. Dumont LJ, Cancelas JA, Graminske S, et al. In vitro and in vivo quality of leukoreduced 
apheresis platelets stored in a new platelet additive solution. Transfusion. 
2013;53(5):972-980. 
8. United States Food and Drug Administration; Blood Products Advisory Committee. New 
Standard for Platelet Evaluation. 2004. 
9. Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Platelet 
Radiolabeling Procedure. Transfusion 2006;46(Suppl 3):59S- 66S. 
10. Deacon B, Abramowitz J. Fear of needles and vasovagal reactions among phlebotomy patients. J Anxiety Disord. 2006;20(7):946-960. 
11. Sorensen BS, Johnsen SP, Jorgensen J. Complications related to blood donation: a 
population-based study. Vox Sang. 2008;94(2):132-137. 
12. Gavillet M, Tissot JD, Ca nellini G. Blood donation associated risks: data from a Swiss 
regional haemovigilance program. Transfus Med. 2013;23(4):269-271. 
13. McLeod BC, Price TH, Owen H, et al. Frequency of immediate adverse effects associated with apheresis donation. Transfusion. 1998;38(10):938-943. 
14. Eder AF, Dy BA, Kennedy JM, et al. The American Red Cross donor hemovigilance 
program: complications of blood donation reported in 2006. Transfusion. 2008;48(9):1809-1819. 
15. Wiltbank TB, Giordano GF. The safety profile of automa ted collections: an analysis of 
more than 1 million collections. Transfusion. 2007;47(6):1002-1005. 
16. Makar YF, Butler MO, Cockersole GM, Gabra G, Serevitch JM. National audit of citrate toxicity in plateletpheresis donors. Transfus Med. 2002;12(3):187-191. 
17. Crocco I, Franchini M, Garozzo G, et al. Adverse reactions in blood and apheresis 
donors: experience from two Italian transfusion centres. Blood Transfus. 2009;7(1):35-
38. 
18. HL Taylor PW, A Heaton. A historical perspective on platelet radiolabeli ng techniques. 
Transfusion. 2006;46:53S-58S. 
19. Program. NCIUCTE. Common Terminology Criteria for Adverse Events:(CTCAE). 
Cancer Therapy Evaluation Program. 2003. 
 
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 45 of 46 Appendix 1  Investigator Signature  
Study Title:   An In Vivo Recovery and Survival Study of Platelets Collected on 
the Trima Accel System and Stored in InterSol Solution   
 
Study  Number  
 
Version/Date:  CTS-5066  
 2.0 / 10 JUL 2017 
I have read the Clinical Investigation Plan (CIP), including all appendices, and I agree that it 
contains all necessary details for me and my staff to conduct this study as described . I will 
conduct this study in compliance with the CIP , GCP, and all applicable regulations. I will make a 
reasonable effort to complete the study within the time designated.  
I will provide all study personnel under my supervision with copies of the CIP and access to  all 
information provided by Terumo BCT. I will discuss this material with them to ensure that they 
are fully informed about the study. 
 
   
Principal Investigator Name (Printed)   Signature  
  
  
Date    
InterSol In Vivo Platelet Quality Study  Terumo BCT, Inc.  
Clinical Investigation Plan: CTS -5066 Version 2 .0: 10 JUL 2017  
Confidential  Page 46 of 46 Appendix 2 BEST Collaborative Platelet Radiolabeling Procedure  